Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162443 | 0.87 | PKM (0.56) | HTTALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL24499496 | 0.86 | NPC1 (0.61) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL29625240 | 0.86 | NPC1 (0.61) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL1385664 | 0.86 | NPC1 (0.61) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL4034877 | 0.86 | ALDH1A1 (0.63) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL6361162 | 0.85 | NPC1 (0.59) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL30259909 | 0.85 | NPC1 (0.59) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL4079701 | 0.85 | SMN1; SMN2 (0.65) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL6290134 | 0.85 | NPC1 (0.59) | NPC1RAB9AHTTPLA2G1BL3MBTL1 | |
| SCHEMBL11863114 | 0.84 | SMN1; SMN2 (0.57) | NPC1RAB9AHTTPLA2G1BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | NPC1 1136/4885RAB9A 1157/4885HTT 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.